STAT Plus: New drug from Merck, Bayer reduces hospitalizations for heart failure patients
An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a study published in the New England Journal of Medicine and presented virtually by the American College of Cardiology on Sunday.
“I think we need to sit back and acknowledge that we have another win in the treatment of heart failure,” Clyde Yancy, chief of cardiology at Northwestern’s Feinberg School of Medicine, said on the ACC’s webcast, speaking about the drug, vericiguat.
Continue to STAT Plus to read the full story…
